# ELVIS ®HSV ID & $\mathbf { D } ^ { 3 }$ Typing Test System

# Applicant:

# AUG 2 8 2009

DIAGNOSTIC HYBRIDS, INC. 1055 East State Street Suite 100 Athens, OHIO 45701

# Contact Information:

Ronald H. Lollar, Senior Director Product Realization, Management, and Marketing   
1055 East State Street   
Suite 100   
Athens, Ohio 45701   
740-589-3300 - Corporate number   
740-589-3373  Desk phone   
740-593-8437  Fax   
lollar@dhiusa.com

# Date of preparation of 510(k) summary:

June 12, 2009

# Device Name:

Trade name - ELVIS®HSV D and ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ Typing Test System   
Common name - HSV Culture and Typing   
Classification name-- Antisera, fluorescent, herpesvirus hominis 1,2   
Product Code - GQL   
Regulation  21 CFR Sec. 866.3305 Herpes simplex virus serological assays; Panel — Microbiology (83)

Legally marketed devices to which equivalence is claimed:

ELVIS®HSV ID/Typing Test System (k971662)

Intended Use:

The ELVIS®HSV ID and D3 Typing Test System provides Cells, Replacement Medium and Test Reagents for the culture, qualitative identification and typing of Herpes simplex virus (HSV) from cutaneous or mucocutaneous specimens collected from patients with clinical suspicion of HSV infection. The performance characteristics of this assay have not been established for antiviral therapy, prenatal monitoring or CSF specimens.

# Device Description:

The ELVIS®HSV D and D3 Typing Test System provides Cells, Replacement Medium and Test Reagents for the culture, qualitative identification and typing of herpes simplex virus (HSV) from cutaneous or mucocutaneous specimens as an aid in the diagnosis of HSV type 1 (HSV-1) and HSV type 2 (HSV-2) infections. The performance characteristics of this assay have not been established for antiviral therapy, prenatal monitoring or use with cerebral spinal fluid specimens.

ELVIS®HSV Cells are genetically engineered Baby Hamster Kidney (BHK) cells, which, when infected with either HSV-1 or HSV-2, are induced to generate and accumulate an endogenous, intracellular bacterial enzyme, $\beta$ - galactosidase. Other related viruses (e.g., Varicella zoster) are not capable of inducing the formation of this enzyme. HSV infection of the ELVIS $\mathrm { \stackrel { \cdot } { \cdot } } \mathrm { \dot { \Phi } } _ { \mathrm { H S V } }$ Cells also results in the formation of HSV-type-specific proteins. The presence of these proteins can be detected microscopically when fluorescent labeled HSV-type-specific antibodies are used. The two Type 1 monoclonal antibodies used in ELVIS® are directed against specific to epitopes on the HSV-1 protein. The three Type 2 monoclonal antibodies are directed against the HSV-2 glycoproteins C, G and a recombinant glycoprotein G that occur in the cytoplasm of infected cells.

The ELVIS®HSV ID and $\mathrm { D } ^ { 3 }$ Typing Test System consists of:

1. ELVIS®HSV Cells: The ELVI $\vec { \mathsf { S } } ^ { \mathfrak { P } } \underline { { \mathsf { H S V } } }$ Cells have a routine use period of 7 days from customer receipt while all other components have a shelflife of months (see expiration date on label of each component). ELVIS®HSV Cells are provided as $7 5 \%$ to $9 5 \%$ confluent monolayers in shell-vials with or without coverslips, or in multi-well plates with or without coverslips, and up to 24 monolayers per plate. Each monolayer is covered by at least $0 . 7 5 – \mathrm { m L }$ of Eagle's Minimum Essential Medium (EMEM) with fetal bovine serum (FBS), penicillin, and streptomycin. Cells are characterized by isoenzyme analysis and have been tested and found free of Mycoplasma spp. and other adventitious organisms. 2. ELVIS®HSV Replacement Medium: Sterile EMEM containing FBS, Penicillin, Streptomycin and Amphotericin B. ELVIS®HSV Replacement Medium is for use with ELVIS $\bar { \mathfrak { G } } \mathrm { \mathbf { { F } } \mathfrak { { S } } V }$ Shell-Vials and Multi-well Plates. 3. ELVIS® HSV Solution 1 (Cell Fixative): an aqueous acetone solution. 4. ELVIS®HSV Solution 2T (Staining Buffer): A diluted solution of XGal (5-Bromo-4-Chloro-3-Indolyl- $\beta$ D-Galactopyranoside), N,N-DimethyIformamide, iron, sodium and magnesium salts, fluorescein-labeled HSV-2-specific murine MAbs (directed against

HSV-2 glycoproteins C, G, and a recombinant glycoprotein G) and nonlabeled HSV-1-specific murine MAbs (specific to epitopes on the HSV.- 1 protein UL42), penicillin, streptomycin, bovine serum albumin and Evans Blue in an aqueous, buffered solution.

5. ELVIS®HSV Solution 3: An aqueous, stabilized, buffered solution containing fluorescein-labeled, affinity purified goat-anti-mouse IgG antibody and Evans Blue with sodium azide as preservative.

6. ELVIS®HSV Mounting Fluid (Buffered Glycerol): Aqueous, stabilized, buffered glycerol $\{ \mathrm { p H } 7 . 3 + / \mathrm { - } 0 . 5 ) $ , containing sodium azide as preservative.

7. 40X PBS Concentrate. 25-mL: One bottle of a 40X PBS concentrate consisting of $0 . 4 \%$ sodium azide $( 0 . 1 \%$ sodium azide after dilution to 1X using de-mineralized water).

# ELVIS®HSV ID & $\mathbf { D } ^ { 3 }$ Typing Test System

# Flowchart of ELVIS® Procedure

<table><tr><td>SET UP</td><td>VIRUS AMPLIFICATION</td><td>COLOR DEVELOPMENT</td><td></td></tr></table>

![](images/6c8fbd8ca4cfccf73d8b9cdd11a10678dd14e043ed9ca833122dcd59ac4366e5.jpg)

# Intended Use:

The ELVIS ${ } ^ { \mathfrak { B } } \mathrm { H S V }$ ID and D3 Typing Test System provides Cells, Replacement Medium and Test Reagents for the culture, qualitative identification and typing of herpes simplex virus (HSV) from cutaneous or mucocutaneous specimens as an aid in the diagnosis of HSV type 1 (HSV-1) and HSV type 2 (HSV-2) infections. The performance characteristics of this assay have not been established for antiviral therapy, prenatal monitoring or use with cerebral spinal fluid specimens.

Technological Characteristics, Compared to Predicate Device:   

<table><tr><td colspan="3" rowspan="1">Table 5.1: Subject Device and Predicate Device Characteristics st</td></tr><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">, "Cx   Item</td><td colspan="1" rowspan="1">Subject Device</td><td colspan="1" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The ELVIS® HSV ID and D3Typing Test System providesCells, Replacement Medium andTest Reagents for the culture,qualitative identification andtyping of Herpes simplex virus(HSV).</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Format</td><td colspan="1" rowspan="1">Shell-vials or Multi-well plates</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay principle</td><td colspan="1" rowspan="1">Genetically engineered BabyHamster Kidney (BHK) cells,which, when infected with eitherHSV-1 or HSV-2, are induced togenerate and accumulate anendogenous, intracellularbacterial enzyme, β-galactosidase.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Labeling Method</td><td colspan="1" rowspan="1">Direct Method -Using fluorescein isothiocyanate(FITC) to label HSV-2 Specificmonoclonal antibodies, and goat-anti-mouse IgG antibody</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Subject Device</td><td colspan="1" rowspan="1"> Predicate Device</td></tr><tr><td colspan="1" rowspan="1">MonoclonalAntibodies(MAbs)</td><td colspan="1" rowspan="1">HSV-1: non-labeled specific toepitopes on the HSV-1 proteinUL42HSV-2: FITC labeled specific</td><td colspan="1" rowspan="1">HSV-1: non-labeled specific toHSV-1 viral protein occurring inthe nuclei of infected cells and anHSV-1 glycoprotein CHSV-2: FITC labeled specific for</td></tr><tr><td colspan="3">Table 5.1: Subject Device and Predicate Device Characteristics </td></tr><tr><td>G</td><td>for HSV-2 glycoproteins C, G, and a recombinant glycoprotein</td><td>HSV-2 glycoproteins C, and G</td></tr></table>

# Performance Testing - Non-Clinical

A. Analytical Sensitivity

Analytical detection limits for HSV-1 and HSV-2 were addressed with results reported in numbers of blue staining cells per cell monolayer. Each master stock $( \mathrm { \sim } 1 \mathrm { e } 7 \mathrm { \mathrm { - } T C I D } _ { 5 0 }$ per mL) virus preparation underwent a series of ten-fold dilutions, which were subsequently inoculated into a 96-well ELVIS®HSV cell culture plate. The plates were centrifuged at $7 0 0 \mathrm { x g }$ for 60 minutes, and then incubated at $3 5 \%$ to $3 7 ^ { \circ } \mathrm { C }$ for 17-hours. Each well was stained with the subject and predicate devices then examined at 200X magnification and the number of blue staining cells counted. Table 5.2. below lists the results for each virus strain tested.

<table><tr><td rowspan=1 colspan=4>Table 5.2. Limit of Detection compared between ELVIS Subject (D³ ELVIS) andPredicate (Current EL VIS Kit Formulation) Typing Systems</td></tr><tr><td rowspan=2 colspan=1>Virus strain</td><td rowspan=2 colspan=1>Virus perInoculum</td><td rowspan=1 colspan=2>Blue staining cells/well</td></tr><tr><td rowspan=1 colspan=1>ELVIS Predicate</td><td rowspan=1 colspan=1>ELVIS Subject</td></tr><tr><td rowspan=5 colspan=1>HSV-1 Strain FATCC VR-733</td><td rowspan=1 colspan=1>65-TCID50</td><td rowspan=1 colspan=1>74, 67, 65, 69, 70, 64</td><td rowspan=1 colspan=1>76, 70, 63, 68, 72, 71</td></tr><tr><td rowspan=1 colspan=1>6.5-TCID50</td><td rowspan=1 colspan=1>9, 8, 11, 7, 7, 12</td><td rowspan=1 colspan=1>10, 9, 9, 11, 7, 13</td></tr><tr><td rowspan=1 colspan=1>0.65-TCID50</td><td rowspan=1 colspan=1>1, 2, 1, 1, 3, 3</td><td rowspan=1 colspan=1>3, 2, 4, 3, 1, 1</td></tr><tr><td rowspan=1 colspan=1>0.065-TCID50</td><td rowspan=1 colspan=1>0, 0, 3, 1, 1, 0</td><td rowspan=1 colspan=1>0,0,1,2,0,0</td></tr><tr><td rowspan=1 colspan=1>0.0065-TCID50</td><td rowspan=1 colspan=1>0, 0, 0, 0, 0, 0</td><td rowspan=1 colspan=1>0,0,0,0,0,0</td></tr><tr><td rowspan=5 colspan=1>HSV-1 CW0H0062Clinical IsolatePassage 2</td><td rowspan=1 colspan=1>85-TCIDs0</td><td rowspan=1 colspan=1>70, 79, 75, 72, 80, 67</td><td rowspan=1 colspan=1>82, 77, 72, 65, 76, 85</td></tr><tr><td rowspan=1 colspan=1>8.5-TCID50</td><td rowspan=1 colspan=1>10,7,7,6, 9,6</td><td rowspan=1 colspan=1>11, 10, 8, 6, 7, 7</td></tr><tr><td rowspan=1 colspan=1>0.85-TCID50</td><td rowspan=1 colspan=1>0, 1, 3, 0, 0, 1, 0</td><td rowspan=1 colspan=1>2, 0, 0, 0, 2, 2</td></tr><tr><td rowspan=1 colspan=1>0.085-TCID50</td><td rowspan=1 colspan=1>0,0, 0, 0, 1, 0</td><td rowspan=1 colspan=1>1,0, 0,0, 1,0</td></tr><tr><td rowspan=1 colspan=1>0.0085-TCID50</td><td rowspan=1 colspan=1>0, 0, 0, 0, 0, 0</td><td rowspan=1 colspan=1>0,0, 0, 0, 0, 0</td></tr><tr><td rowspan=4 colspan=1>HSV-1 CWOH0085Clinical IsolatePassage 2</td><td rowspan=1 colspan=1>60-TCID50</td><td rowspan=1 colspan=1>39, 47, 52, 41, 42, 48</td><td rowspan=1 colspan=1>46, 48, 37, 42, 47, 50</td></tr><tr><td rowspan=1 colspan=1>6.0-TCID50</td><td rowspan=1 colspan=1>6, 10, 11, 8, 7, 15</td><td rowspan=1 colspan=1>7,14, 9, 8,11,7</td></tr><tr><td rowspan=1 colspan=1>0.6-TCID50</td><td rowspan=1 colspan=1>2, 0, 2, 0, 0, 1</td><td rowspan=1 colspan=1>1, 1, 0, 0, 0, 1</td></tr><tr><td rowspan=1 colspan=1>0.06-TCID50</td><td rowspan=1 colspan=1>0,0, 0,0,0, 0</td><td rowspan=1 colspan=1>0,0, 0, 0,0, 0</td></tr><tr><td rowspan=5 colspan=1>HSV-2 G StrainATCC VR-734</td><td rowspan=1 colspan=1>100-TCD50</td><td rowspan=1 colspan=1>92, 102, 95, 91, 97,90</td><td rowspan=1 colspan=1>95, 96, 97, 98, 89, 103</td></tr><tr><td rowspan=1 colspan=1>10-TCID50</td><td rowspan=1 colspan=1>12, 11, 17, 9, 9, 10</td><td rowspan=1 colspan=1>12, 12, 7, 16, 13, 12</td></tr><tr><td rowspan=1 colspan=1>1.0-TCID50</td><td rowspan=1 colspan=1>3, 2, 1, 1, 3, 4</td><td rowspan=1 colspan=1>5, 1, 2, 2, 1, 3</td></tr><tr><td rowspan=1 colspan=1>0.1-TCID50</td><td rowspan=1 colspan=1>0, 1, 0, 1, 0, 0</td><td rowspan=1 colspan=1>1, 0, 0, 0, 1, 1</td></tr><tr><td rowspan=1 colspan=1>0.01-TCID50</td><td rowspan=1 colspan=1>0,0,0,0, 0, 0</td><td rowspan=1 colspan=1>0,0,0,0,0,0</td></tr></table>

# ELVIS®HSV ID & $\mathbf { D } ^ { 3 }$ Typing Test System

<table><tr><td rowspan=1 colspan=4>Table 5.2 Limit of Detection compared between ELVIS Subject (D² ELVIS) andPredicate (Current EL VIS Kit Formulation) Typing Systems   e</td></tr><tr><td rowspan=5 colspan=1>HSV-2 CWOH0082Clinical IsolatePassage 2</td><td rowspan=1 colspan=1>80-TCID50</td><td rowspan=1 colspan=1>70, 67, 73, 78, 70, 62</td><td rowspan=1 colspan=1>76, 77, 64, 80, 70, 69</td></tr><tr><td rowspan=1 colspan=1>8.0-TCID50</td><td rowspan=1 colspan=1>8, 7, 10, 11, 6, 5</td><td rowspan=1 colspan=1>7, 8, 14, 11, 11, 9</td></tr><tr><td rowspan=1 colspan=1>0.8-TCID50</td><td rowspan=1 colspan=1>1, 0, 3, 3, 2, 2, 1</td><td rowspan=1 colspan=1>2, 1, 1, 3, 1, 0</td></tr><tr><td rowspan=1 colspan=1>0.08-TCID50</td><td rowspan=1 colspan=1>0,0, 1, 0, 0, 0</td><td rowspan=1 colspan=1>0,1,0,0,0,0</td></tr><tr><td rowspan=1 colspan=1>0.008-TCID50</td><td rowspan=1 colspan=1>0,0, 0, 0, 0, 0</td><td rowspan=1 colspan=1>0,0,0,0,0,0</td></tr><tr><td rowspan=5 colspan=1>HSV-2 CWOH0091Clinical IsolatePassage 2</td><td rowspan=1 colspan=1>55-TCID50</td><td rowspan=1 colspan=1>53, 61, 55, 62, 67, 65</td><td rowspan=1 colspan=1>70, 62, 55, 57, 53, 59</td></tr><tr><td rowspan=1 colspan=1>5.5-TCID50</td><td rowspan=1 colspan=1>3, 7, 7, 9, 2, 4</td><td rowspan=1 colspan=1>4, 4, 7, 8, 10, 3</td></tr><tr><td rowspan=1 colspan=1>0.55-TCID50</td><td rowspan=1 colspan=1>1, 0, 0, 2, 2, 1</td><td rowspan=1 colspan=1>3, 1, 0, 0, 2, 2</td></tr><tr><td rowspan=1 colspan=1>0.055-TCID50</td><td rowspan=1 colspan=1>0,0, 0, 1, 0, 0</td><td rowspan=1 colspan=1>1,0, 0, 0, 0, 0</td></tr><tr><td rowspan=1 colspan=1>0.0055-TCID50</td><td rowspan=1 colspan=1>0,0,0,0,0,0</td><td rowspan=1 colspan=1>0,0,0, 0,0,0</td></tr></table>

In this study, the detection limit for the test is defined as the lowest inoculum level at which positive wells (i.e., containing blue staining cells) are observed, in terms of $\mathrm { T C I D } _ { 5 0 }$ . The results presented in Table 5.2 above indicate that detection limit for both subject and predicate devices averages between 0.65- and $8 . 5 \mathrm { - } \mathrm { T C I D } _ { 5 0 }$ for HSV-1 and 0.1 and $8 . 0 { - } \mathrm { T C I D } _ { 5 0 }$ for HSV-2 depending on the strain.

# B. Cross Reactivity

The specificity of the MAbs used in the device was assessed using the organisms listed in Table 5.3. The subject device Solution $2 T$ at 2X concentration was tested in duplicate on the prepared slides. After 1-hour at $3 7 ^ { \circ } \mathrm { C }$ , the slides were rinsed with PBS and the subject device Solution 3 secondary stain was added and incubated at $3 7 ^ { \circ } C$ for 15 minutes. After rinsing and applying Mounting Fluid, the slides were examined at 400X using a fluorescence microscope.

<table><tr><td rowspan=1 colspan=4>Table 5.3: Respiratory Cross-Reactivity Testing A88X0X9X0X*xy                            CR</td></tr><tr><td rowspan=1 colspan=1>Organism</td><td rowspan=1 colspan=1>Strain or Type</td><td rowspan=1 colspan=1>ELVIS HSV TypingReagent at 2Xconcentration[Positive (+) orNegative (-) forReactivity</td><td rowspan=1 colspan=1>Concentrations oftargets (viruses:TCID5o inoculumlevel; bacteria:CFU</td></tr><tr><td rowspan=1 colspan=4>Viruses   .                                                                        *       , ita</td></tr><tr><td rowspan=5 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 1</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Type 3</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Type 5</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Type 6</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Type 7</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr></table>

# ELVIS®HSV ID & $\mathbf { D } ^ { 3 }$ Typing Test System

<table><tr><td rowspan=6 colspan=1></td><td rowspan=1 colspan=1>Type 8</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Type 10</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Type 13</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Type 14</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Type 18</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Type 31</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=9 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Aichi (H3N2)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Mal (H1N1)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Hong Kong (H3N2)</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Denver (H1N1)</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Port Chalmers(H3N2)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Victoria (H3N2)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>New Jersey(HSWN1)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>WS (H1N1)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>PR (H1N1)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=7 colspan=1>Influenza B</td><td rowspan=1 colspan=1>Hong Kong</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Maryland</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Mass</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>GL</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Taiwan</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>JH-001 Isolate</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Russia</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=3 colspan=1>RSV</td><td rowspan=1 colspan=1>Long</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Wash</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>9320</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 1</td><td rowspan=1 colspan=1>C-35</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 2</td><td rowspan=1 colspan=1>Greer</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 3</td><td rowspan=1 colspan=1>C-243</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 4</td><td rowspan=1 colspan=1>M-25</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1000-TCD50</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 4b</td><td rowspan=1 colspan=1>CH-19503</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1000-TCID50</td></tr><tr><td rowspan=1 colspan=1>CMV</td><td rowspan=1 colspan=1>AD169</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Control Slide</td></tr><tr><td rowspan=1 colspan=1>Varicella-zoster</td><td rowspan=1 colspan=1>Webster</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Control Slide</td></tr><tr><td rowspan=1 colspan=1>Echovirus 7</td><td rowspan=1 colspan=1>ODH-594684</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>Control Slide</td></tr><tr><td rowspan=1 colspan=1>Coxsackievirus A9</td><td rowspan=1 colspan=1>ODH-36685</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Control Slide</td></tr><tr><td rowspan=1 colspan=1>Coxsackievirus B2</td><td rowspan=1 colspan=1>ODH-185</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Control Slide</td></tr><tr><td rowspan=1 colspan=1>Enterovirus 71</td><td rowspan=1 colspan=1>ODH 02-89</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Control Slide</td></tr><tr><td rowspan=1 colspan=4>Racteria*                                                                                          </td></tr></table>

# ELVIS®HSV ID & $\mathbf { D } ^ { 3 }$ Typing Test System

<table><tr><td rowspan=1 colspan=1>Acinetobactercalcoaceticus</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3.6x10 CFU</td></tr><tr><td rowspan=1 colspan=1>Bordetella bronchiseptica</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1.1x10^0 CFU</td></tr><tr><td rowspan=1 colspan=1>Bordetella pertussis</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4.3x10 CFU</td></tr><tr><td rowspan=1 colspan=1>Chlamydia trachomatis</td><td rowspan=1 colspan=1>LGV-II</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Control Slide</td></tr><tr><td rowspan=1 colspan=1>Corynebacteriumdiphtheriae</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>5.7x10&#x27; CFU</td></tr><tr><td rowspan=1 colspan=1>Escherichia coli</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>7.5x10° CFU</td></tr><tr><td rowspan=1 colspan=1>Haemophilis influenzaetype A</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4.1x10° CFU</td></tr><tr><td rowspan=1 colspan=1>Klebsiella pneumoniae</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1.2x10 CFU</td></tr><tr><td rowspan=1 colspan=1>Moraxella cartarrhalis</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1.2x10 CFU</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma hominis</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3.5x101 CFU</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma orale</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>6.6x10 CFU</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma pneumoniae</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>7.9x10 CFU</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma salivarium</td><td rowspan=1 colspan=1>cYanmaGentaYelowb</td><td rowspan=1 colspan=1>cYanmaGentaYYellowb</td><td rowspan=1 colspan=1>7.7x108 CFU</td></tr><tr><td rowspan=1 colspan=1>Proteus mirabilis</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3.6x10 CFU</td></tr><tr><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1.0x10$CFU</td></tr><tr><td rowspan=1 colspan=1>Salmonella enteriditis</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>8.7x10 CFU</td></tr><tr><td rowspan=1 colspan=1>Salmonella typhimurium</td><td rowspan=1 colspan=1>cYanmaGentaYellowb</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>7.5x10 CFU</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+}$</td><td rowspan=1 colspan=1>6.3x10 CFU</td></tr><tr><td rowspan=1 colspan=1>Streptococcus agalactiae</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>canmaGentaYelow</td><td rowspan=1 colspan=1>5.5x10 CFU</td></tr><tr><td rowspan=1 colspan=1>Streptococcus pneumoniae</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>6.7x10 CFU</td></tr><tr><td rowspan=1 colspan=1>Streptococcus pyogenes</td><td rowspan=1 colspan=1>cYanmaGntaYelow</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>6.9x10 CFU</td></tr><tr><td rowspan=1 colspan=4>Yeast                                                                         </td></tr></table>

<table><tr><td>Candida glabrata</td><td></td><td>-</td><td>1.6x10 CFU</td></tr></table>

\*Turbidity or a color change to yellow indicates possible bacterial contamination and may render a test result unreliable, due either to a technical contamination during the culture setup or to a contaminated specimen. We recommend the original specimen be filtered and re-cultured.

† Light background fluorescent staining may occur with specimens contaminated with Staphylococcus aureus strains containing large amounts of protein A. Protein A binds to the Fc portions of the conjugated antibodies. Such binding can be distinguished from viral antigen binding on the basis of morphology, e.g., S. aureus-bound fluorescence appears as small ( $- 1$ micron diameter), bright dots.

# C. Reproducibility Testing

The reproducibility of the device was assessed by creating ten panels of proficiency-level frozen virus suspensions. The panels were processed at each testing site. Each panel was inoculated and stained once according to the ELVIS ${ } ^ { \mathfrak { G } } { \mathrm { ~ H S V } }$ ID and $D ^ { 3 }$ Typing Test System instructions for use. Two panels per day were tested on separate plates for 5-days (10 total runs).

Panel members were manufactured by diluting high-titered master stocks. The dilutions were made with the same lot of EMEM with $10 \%$ Fetal Bovine Serum used as the negative control. These dilutions were frozen at $- 7 0 \%$ and sent to the testing labs. The dilution's titer was confirmed pre- and post freezing and found to fall within the expected infectivity range for the study: low level should exhibit less than $10 \%$ of the cells showing fluorescence; high level should exhibit greater than $10 \%$ but less than $50 \%$ of the cells showing fluorescence.

<table><tr><td rowspan=1 colspan=2>Table 5.4: Panel Member Discriptions</td></tr><tr><td rowspan=1 colspan=1>Panel Member</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>canmantaYlowb</td><td></td></tr><tr><td rowspan=1 colspan=1>HSV-1 low level</td><td rowspan=1 colspan=1>SF029* lab adapted QC strain; 200 TCID50/mL</td></tr><tr><td rowspan=1 colspan=1>HSV-1 high level</td><td rowspan=1 colspan=1>SF029 lab adapted QC strain; 1000 TCID5o/mL</td></tr><tr><td rowspan=1 colspan=1>HSV-2 low level</td><td rowspan=1 colspan=1>SF028† lab adapted QC strain; 200 TCID5o/mL</td></tr><tr><td rowspan=1 colspan=1>HSV-2 high level</td><td rowspan=1 colspan=1>SF028 lab adapted QC strain; 1000 TCIDso/mL</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>EMEM with 10% Fetal Bovine Serum</td></tr></table>

\*Isolate confirmed as HSV-1 by 2 FDA cleared IVD devices †Isolate confirmed as HSV-2 by 2 FDA cleared IVD devices

Table 5.5 presents the daily results from each panel member at each site.   

<table><tr><td rowspan=1 colspan=12>Table5.5: Daily Results                                                           o0G:</td></tr><tr><td rowspan=1 colspan=1>PanelMember</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Day 1</td><td rowspan=1 colspan=2>Day 2</td><td rowspan=1 colspan=2>Day 3</td><td rowspan=1 colspan=2>Day 4</td><td rowspan=1 colspan=2>Day 5</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Run1</td><td rowspan=1 colspan=1>Run2</td><td rowspan=1 colspan=1>Run1</td><td rowspan=1 colspan=1>Run2</td><td rowspan=1 colspan=1>Run1</td><td rowspan=1 colspan=1>Run2</td><td rowspan=1 colspan=1>Run1</td><td rowspan=1 colspan=1>Run2</td><td rowspan=1 colspan=1>Run1</td><td rowspan=1 colspan=1>Run2</td></tr><tr><td rowspan=3 colspan=1>HSV-1low level</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>+1-</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>+1-</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>+1-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>+1-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+1-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+1-</td><td rowspan=1 colspan=1>1+</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td></tr><tr><td rowspan=3 colspan=1>HSV-1high level</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1 to2+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>2+</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>2+</td></tr><tr><td rowspan=3 colspan=1>HSV-2low level</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/1-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>+1-</td><td rowspan=1 colspan=1>+1-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>1 to2+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>2+</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+1-</td><td rowspan=1 colspan=1>1+</td></tr><tr><td rowspan=3 colspan=1>HSV-2high level</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>2+</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>2+</td></tr><tr><td rowspan=2 colspan=1>Negative</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td></tr></table>

# ELVIS®HSV ID & D Typing Test System

<table><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td></tr></table>

The presence of HSV was reported in $100 \%$ (120/120) of the wells in which infected cells were present and the expected type was reported $100 \%$ (60/60) for HSV-1 and $100 \%$ (60/60) for HSV-2. The absence of HSV was reported in $100 \%$ (30/30) of the vials in which no virus was present. Controls performed as expected during each run.

<table><tr><td rowspan=1 colspan=8>Table 5.6: Reproducibility Study Summary Results</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>PanelMember</td><td rowspan=1 colspan=1>HSVSF029Low Level</td><td rowspan=1 colspan=1>HSV-1SF029Mid Level</td><td rowspan=1 colspan=1>HSV-2SF028Low Level</td><td rowspan=1 colspan=1>HSV-2SF028Mid Level</td><td rowspan=1 colspan=1>NegativeControl</td><td rowspan=1 colspan=1>Total %Agreement</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>200TCID50/mL</td><td rowspan=1 colspan=1>1000TCID50/mL</td><td rowspan=1 colspan=1>200TCID50/mL</td><td rowspan=1 colspan=1>1000TCD50/mL</td><td rowspan=1 colspan=1>Non-infectedcells</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>Agreement withExpected result</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>50/50(100%)</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Agreement withExpected result</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>50/50(100%)</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>Agreement withExpected result</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>10/10(100%)</td><td rowspan=1 colspan=1>50/50(100%)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total Agreementwith Expectedresult</td><td rowspan=1 colspan=1>30/30(100%)</td><td rowspan=1 colspan=1>30/30(100%)</td><td rowspan=1 colspan=1>30/30(100%)</td><td rowspan=1 colspan=1>30/30(100%)</td><td rowspan=1 colspan=1>30/30(100%)</td><td rowspan=1 colspan=1>150/150(100%)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>88.4%-100%</td><td rowspan=1 colspan=1>88.4%-100%</td><td rowspan=1 colspan=1>88.4%-100%</td><td rowspan=1 colspan=1>88.4%-100%</td><td rowspan=1 colspan=1>88.4%-100%</td><td rowspan=1 colspan=1>97.6%-100%</td></tr></table>

# Performance Testing - Clinical

Studies were performed at three locations using 735 specimens submitted, April through May, 2009, for HSV culture. The number of specimens cultured at each of the three sites: Study site 1 - 299 specimens; Study site 2 - 136 specimens; and Study site 3 - 300 specimens. The specimens were cultured in duplicate and stained concurrently with both devices. The data generated by each site was similar and has been combined for presentation. Of these 735 specimens, 16 were excluded from the final analysis for the reasons listed in Table 5.7.

<table><tr><td rowspan=1 colspan=2>Table 5.7. Combined Study Sites Rejected&lt;MirSpecimens/Samples</td></tr><tr><td rowspan=1 colspan=1>Exclusion criteria - Toxic to cell culture</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Exclusion criteria - Contaminated</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Grand Total</td><td rowspan=1 colspan=1>16</td></tr></table>

Table 5.8 shows the age and gender distribution for individuals included in the Study:

Table 5.9 shows the specimen source distribution for the Study:   

<table><tr><td rowspan=1 colspan=4>40998(720 Specimens)                     t   3×</td></tr><tr><td rowspan=2 colspan=1>Age Range</td><td rowspan=1 colspan=3>Values are # Positive (based on Subject Device) /Total</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>0 to 1 month</td><td rowspan=1 colspan=1>0/9</td><td rowspan=1 colspan=1>1/9</td><td rowspan=1 colspan=1>1/18</td></tr><tr><td rowspan=1 colspan=1>&gt;1 month to 2 years</td><td rowspan=1 colspan=1>0/1</td><td rowspan=1 colspan=1>0/1</td><td rowspan=1 colspan=1>0/2</td></tr><tr><td rowspan=1 colspan=1>&gt;2 to 12 years</td><td rowspan=1 colspan=1>1/7</td><td rowspan=1 colspan=1>4/7</td><td rowspan=1 colspan=1>5/14</td></tr><tr><td rowspan=1 colspan=1>&gt;12 to 21 years</td><td rowspan=1 colspan=1>4/22</td><td rowspan=1 colspan=1>54/110</td><td rowspan=1 colspan=1>58/132</td></tr><tr><td rowspan=1 colspan=1>22 to 30 years</td><td rowspan=1 colspan=1>9/34</td><td rowspan=1 colspan=1>71/146</td><td rowspan=1 colspan=1>80/180</td></tr><tr><td rowspan=1 colspan=1>31 to 40 years</td><td rowspan=1 colspan=1>10/37</td><td rowspan=1 colspan=1>44/121</td><td rowspan=1 colspan=1>54/158</td></tr><tr><td rowspan=1 colspan=1>41 to 50 years</td><td rowspan=1 colspan=1>8/22</td><td rowspan=1 colspan=1>18/64</td><td rowspan=1 colspan=1>26/86</td></tr><tr><td rowspan=1 colspan=1>51 to 60 years</td><td rowspan=1 colspan=1>3/14</td><td rowspan=1 colspan=1>15/50</td><td rowspan=1 colspan=1>18/64</td></tr><tr><td rowspan=1 colspan=1>&gt;60 years</td><td rowspan=1 colspan=1>3/18</td><td rowspan=1 colspan=1>9/47</td><td rowspan=1 colspan=1>12/65</td></tr><tr><td rowspan=1 colspan=1>Unknown age</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>0/0</td></tr><tr><td rowspan=1 colspan=1>Grand Total</td><td rowspan=1 colspan=1>38/165</td><td rowspan=1 colspan=1>216/555</td><td rowspan=1 colspan=1>254/719</td></tr></table>

<table><tr><td rowspan=1 colspan=17>Table 5.9: Combined Study Sites - Specimen Source Distribution (719 Specimens)Values are # Positive (based on Subject Device) / Total</td></tr><tr><td rowspan=1 colspan=1>Sunee</td><td rowspan=1 colspan=1>SecmnsM</td><td rowspan=1 colspan=1>1+ unoutun</td><td rowspan=1 colspan=1> Cfil</td><td rowspan=1 colspan=1>-/+ sud</td><td rowspan=1 colspan=1>+n\</td><td rowspan=1 colspan=1>1+ !q7</td><td rowspan=1 colspan=1>Ccc</td><td rowspan=1 colspan=1>-/+ punoM</td><td rowspan=1 colspan=1>+  wnd</td><td rowspan=1 colspan=1>-/+A|A</td><td rowspan=1 colspan=1>H</td><td rowspan=1 colspan=1>-/+ Losa1</td><td rowspan=1 colspan=1>+2</td><td rowspan=1 colspan=1>-/+ ** 4o</td><td rowspan=1 colspan=1>-1+us</td><td rowspan=1 colspan=1>Berg¥</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>254/719</td><td rowspan=1 colspan=1>66/175</td><td rowspan=1 colspan=1>18/50</td><td rowspan=1 colspan=1>14/44</td><td rowspan=1 colspan=1>451105</td><td rowspan=1 colspan=1>23/47</td><td rowspan=1 colspan=1>18/50</td><td rowspan=1 colspan=1>0/4</td><td rowspan=1 colspan=1>16/40</td><td rowspan=1 colspan=1>23/66</td><td rowspan=1 colspan=1>0/12</td><td rowspan=1 colspan=1>5114</td><td rowspan=1 colspan=1>4132</td><td rowspan=1 colspan=1>9137</td><td rowspan=1 colspan=1>13/42</td><td rowspan=1 colspan=1>1/1</td></tr><tr><td rowspan=1 colspan=17>Pncu: anal, groin, buttock, perianal, tailbone**M:muh, lip, thrat, NP Wash, Tnue   Face: cheek, chin, eye, nasal</td></tr></table>

Table 5.10 shows the comparison of the Subject device with the Predicate device for the isolation and detection of HSV at Study Sites Combined:   

<table><tr><td rowspan=1 colspan=4>Table 5.10: Combined Study Sites - Subject Device compared tob0                            Predicate Device for the Isolation of HSV    S    i &#x27;s</td></tr><tr><td rowspan=1 colspan=1>Specimen (719 specimens)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Predicate Device(Current ELVIS Kit Formulation)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>Subject Device (D³ ELVIS)</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>463</td></tr><tr><td rowspan=1 colspan=2>Positive Percent Agreement (PPA)</td><td rowspan=1 colspan=1>99.6% (250/251)</td><td rowspan=2 colspan=1></td></tr><tr><td rowspan=1 colspan=2>95% CI-PPA</td><td rowspan=1 colspan=1>97.8 - 100%</td></tr><tr><td rowspan=1 colspan=2>Negative Percent Agreement (NPA)</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>98.9% (463/468)</td></tr><tr><td rowspan=1 colspan=2>95% CI-NPA</td><td rowspan=1 colspan=1>97.5 - 99.7%</td></tr></table>

Table 5.11 shows the comparison of the Subject device with the Predicate device for the identification of HSV-2 at Study Sites Combined:   

<table><tr><td rowspan=1 colspan=4>Table 5.11:       Combined Study Sites - Subject Device comparedto Predicate Device for the Typing of HSV-2miod w,1uYn      ,t.</td></tr><tr><td rowspan=1 colspan=1>Specimen (106specimens)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Predicate Device HSV-2(Current ELVIS Kit Formulation)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>Subject Device HSV-2(D^3 ELVIS)</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>145</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=2>Positive Percent Agreement (PPA)</td><td rowspan=1 colspan=1>99.3% (145/146)</td><td rowspan=2 colspan=1></td></tr><tr><td rowspan=1 colspan=2>95% CI-PPA</td><td rowspan=1 colspan=1>96.2 - 100%</td></tr><tr><td rowspan=1 colspan=2>Negative Percent Agreement(NPA)</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>94.2% (98/104)</td></tr><tr><td rowspan=1 colspan=2>95% CI-NPA</td><td rowspan=1 colspan=1>87.9 - 97.9%</td></tr></table>

Table 5.12 shows the comparison of the Subject device with the Predicate device for the identification of HSV-2 at Study Sites Combined:   

<table><tr><td rowspan=1 colspan=4>Table 5.12:       Combined Study Sites- Subject Device comparedto Predicate Device for the Typing of HSV-1</td></tr><tr><td rowspan=1 colspan=1>Specimen (36 specimens)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Predicate Device HSV-1(Current ELVIS Kit Formulation)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>Subject Device HSV-1(D^3 ELVIS)</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=2>Positive Percent Agreement (PPA)</td><td rowspan=1 colspan=1>100% (32/32)</td><td rowspan=1 colspan=1></td></tr></table>

# ELVIS®HSV ID & $\mathbf { D } ^ { 3 }$ Typing Test System

<table><tr><td rowspan=1 colspan=1>95% CI-PPA</td><td rowspan=1 colspan=1>96.0 - 100%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Negative Percent Agreement (NPA)</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>87.5% (7/8)</td></tr><tr><td rowspan=1 colspan=1>95% CI-NPA</td><td rowspan=1 colspan=1>47.3 - 99.7%</td></tr></table>

The analytical testing and study results from the combined sites demonstrate that the $\mathrm { E L V I S } ^ { \mathrm { \textregistered } } \mathrm { H S V }$ ID and $\mathrm { D } ^ { 3 }$ Typing Test System results when compared to the results obtained with the FDA-cleared ELVIS ${ \mathfrak { P } } _ { \mathrm { H S V } }$ ID/Typing Test System demonstrated adequate performance to be considered substantially equivalent for the qualitative isolation and identification of HSV-1 and HSV-2 in ELVIS ${ } ^ { \mathfrak { B } } \mathrm { H S V }$ cell cultures.

# AUG 2 8 2009

Ronald H. Lollar Diagnostic Hybrids, Inc. 1055 East State Street Suite 100 Athens, Ohio 45701

Re: K091753 Trade/Device Name: ELVIS HSV ID and $\mathsf { D } ^ { 3 }$ Typing Test System Regulation Number: 21 CFR 866.3305 Regulation Name: Herpes simplex virus serological assays Regulatory Class: Class ⅡI Product Code: GQL Dated: June 12, 2009 Received: June 16, 2009

Dear Mr. Lollar:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

Page 2 - Mr. Lollar

CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours,   
Jall attpr   
Sally Hojvat, M.Sc.Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

510(k) Number (if known): k091753

# Device Name: ELVIS® HSV ID and $\mathbf { D } ^ { 3 }$ Typing Test System

Indications For Use:

The ELVIS®HSV ID and D3 Typing Test System provides Cells, Replacement Medium and Test Reagents for the culture, qualitative identification and typing of herpes simplex virus (HSV) from cutaneous or mucocutaneous specimens as an aid in the diagnosis of HSV type 1 (HSV-1) and HSV type 2 (HSV-2) infections. The performance characteristics of this assay have not been established for antiviral therapy, prenatal monitoring or use with cerebral spinal fluid specimens.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/1ffb6bcfd05d62bc4b7f8c4bbbfd98b1f70e2db451f9f2831c55e1f2ef847970.jpg)  
Page 1 of 1

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) 091753